During his first official press conference as U.S. President Elect, Donald Trump took aim at American pharmaceuticals. According to Trump, one of his many acts as Commander In Chief will be to bring pharmaceutical drug prices and spending down as well as change the way the United States of America bids on pharmaceutical drugs.
"Pharma has a lot of lobbies, a lot of lobbyists and a lot of power. And there's very little bidding on drugs. We're the largest buyer of drugs in the world, and yet we don't bid properly," said Trump.
Trump did not unveil or allude to any plan in specific to change the way the U.S. prices and purchases pharmaceuticals. Many political pundits believe that he will find it difficult to bring his plan to fruition. United States of America federal law forbids the U.S. government from ever negotiating with drug companies in order to lower the prices of drugs for senior citizens under Medicare. Trump has, in the past, called for allowing Medicare to negotiate on drug prices for senior citizens.
"I think the most valuable lesson learned is that the pricing model has got to change. It's not incremental change; I don't think that's what this country needs. I think it's truly rethinking the business model," said Mylan Pharmaceuticals CEO, Heather Bresch. "I know that scares a lot of people. ... If anybody is walking away from this conference thinking 'business as usual,' I think that's a mistake."